» Articles » PMID: 36748513

Suppression of Innate Immunity by the Vaccinia Virus Protein N1 Promotes Skin Microbiota Expansion and Increased Immune Infiltration Following Vaccination

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2023 Feb 7
PMID 36748513
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccinia virus (VACV) protein N1 is an intracellular immunomodulator that contributes to virus virulence via inhibition of NF-κB. Intradermal infection with a VACV lacking gene (vΔN1) results in smaller skin lesions than infection with wild-type virus (WT VACV), but the impact of N1 deletion on the local microbiota as well as the innate and cellular immune responses in infected ear tissue is mostly uncharacterized. Here, we analysed the bacterial burden and host immune response at the site of infection and report that the presence of protein N1 correlated with enhanced expansion of skin microbiota, even before lesion development. Furthermore, early after infection (days 1-3), prior to lesion development, the levels of inflammatory mediators were higher in vΔN1-infected tissue compared to WT VACV infection. In contrast, infiltration of ear tissue with myeloid and lymphoid cells was greater after WT VACV infection and there was significantly greater secondary bacterial infection that correlated with greater lesion size. We conclude that a more robust innate immune response to vΔN1 infection leads to better control of virus replication, less bacterial growth and hence an overall reduction of tissue damage and lesion size. This analysis shows the potent impact of a single viral immunomodulator on the host immune response and the pathophysiology of VACV infection in the skin.

References
1.
Maluquer de Motes C, Cooray S, Ren H, Almeida G, McGourty K, Bahar M . Inhibition of apoptosis and NF-κB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog. 2011; 7(12):e1002430. PMC: 3240604. DOI: 10.1371/journal.ppat.1002430. View

2.
Aoyagi M, Zhai D, Jin C, Aleshin A, Stec B, Reed J . Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci. 2006; 16(1):118-24. PMC: 2222835. DOI: 10.1110/ps.062454707. View

3.
Graham S, Bahar M, Cooray S, Chen R, Whalen D, Abrescia N . Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog. 2008; 4(8):e1000128. PMC: 2494871. DOI: 10.1371/journal.ppat.1000128. View

4.
Albarnaz J, Torres A, Smith G . Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory. Viruses. 2018; 10(3). PMC: 5869494. DOI: 10.3390/v10030101. View

5.
Smith G, Benfield C, Maluquer de Motes C, Mazzon M, Ember S, Ferguson B . Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. J Gen Virol. 2013; 94(Pt 11):2367-2392. DOI: 10.1099/vir.0.055921-0. View